Lanreotide acetate

Lanreotide acetate (CAS No.: 2378114-72-6) is a synthetic peptide analog of the endogenous neuroendocrine regulator somatostatin and is broadly classified as an endocrine and oncology relevant research molecule for mechanistic studies in biomedical science and drug discovery, with primary activity associated with high affinity engagement of somatostatin receptor signaling, especially receptor subtypes commonly linked to suppression of cyclic AMP dependent secretory programs and modulation of calcium and potassium channel linked cellular excitability in neuroendocrine systems; consistent with this pharmacological class, it is used to investigate growth hormone regulatory biology, secretory pathway control, and antiproliferative signaling networks in tumor associated cellular contexts, including pathway level effects on receptor mediated inhibition of hormone release, cell cycle related signaling tone, and downstream kinase transcriptional responses, while published potency patterns for this class are generally described within nanomolar to low micromolar concentration ranges depending on receptor expression profile, assay format, and endpoint selection; in practical research workflows, lanreotide acetate is commonly applied in receptor pharmacology assays, endocrine cell and neuroendocrine tumor cell model studies, and in vivo experimental systems designed to characterize biomarker dynamics, target engagement, and combination strategy hypotheses, with the concentrations or doses used in experiments typically depending on specific experimental designs and research objectives, and with all use limited to controlled laboratory research settings rather than any human use or other non research applications.